scholarly journals CTS™ immune cell SR for serum free culture and expansion of human T cells

2015 ◽  
Vol 3 (Suppl 2) ◽  
pp. P1
Author(s):  
Grethe Okern ◽  
Angel Varela-Rohena ◽  
Sandra Kuligowski ◽  
Brian Newsom ◽  
Tanja Aarvak
Keyword(s):  
T Cells ◽  
Cytotherapy ◽  
2015 ◽  
Vol 17 (6) ◽  
pp. S77
Author(s):  
Karoline Schjetne ◽  
Grethe Økern ◽  
Sandra Kuligowski ◽  
Angel Varela-Rohena ◽  
Tanja Aarvak
Keyword(s):  
T Cells ◽  

eLife ◽  
2019 ◽  
Vol 8 ◽  
Author(s):  
Enas Abu-Shah ◽  
Philippos Demetriou ◽  
Štefan Bálint ◽  
Viveka Mayya ◽  
Mikhail A Kutuzov ◽  
...  

Research in the field of human immunology is restricted by the lack of a system that reconstitutes the in-situactivation dynamics of quiescent human antigen-specific T-cells interacting with dendritic cells. Here we report a tissue-like system that recapitulates the dynamics of engineered primary human immune cell. Our approach facilitates real-time single-cell manipulations, tracking of interactions and functional responses complemented by population-based measurements of cytokines, activation status and proliferation. As a proof of concept, we recapitulate immunological phenomenon such as CD4 T-cells' help to CD8 T-cells through enhanced maturation of DCs and the effect of PD-1 checkpoint blockades. In addition, we characterise unique dynamics of T-cell/DC interactions as a function of antigen affinity.


2021 ◽  
Author(s):  
Jessica Margaret Sido ◽  
James B Hemphill ◽  
Rameech N McCormack ◽  
Ross D Beighley ◽  
Bethany F Grant ◽  
...  

Non-viral approaches to transfection have emerged a viable option for gene transfer. Electro-mechanical transfection involving use of electric fields coupled with high fluid flow rates is a scalable strategy for cell therapy development and manufacturing. Unlike purely electric field-based or mechanical-based delivery methods, the combined effects result in delivery of genetic material at high efficiencies and low toxicity. This study focuses on delivery of reporter mRNA to show electro-mechanical transfection can be used successfully in human T cells. Rapid optimization of delivery to T cells was observed with efficiency over 90% and viability over 80%. Confirmation of optimized electro-mechanical transfection parameters was assessed in multiple use cases including a 50-fold scale up demonstration. Transcriptome and ontology analysis show that delivery, via electro-mechanical transfection, does not result in gene dysregulation. This study demonstrates that non-viral electro-mechanical transfection is an efficient and scalable method for cell and gene therapy engineering and development.


2015 ◽  
Vol 4 (1) ◽  
pp. e31 ◽  
Author(s):  
Corey Smith ◽  
Grethe Økern ◽  
Sweera Rehan ◽  
Leone Beagley ◽  
Sau K Lee ◽  
...  

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 5247-5247
Author(s):  
María L. Lamana ◽  
Rosa M. Yañez ◽  
Juan A. Bueren

Abstract Aiming to control GVHD by means of the transfer of suicide genes into donor T cells, we seeked to optimise the transduction of human T cells using immobilized anti-CD3i/28i MoAbs for T cell stimulation. In previous studies we showed that reducing the concentration of anti-CD3i, from 1,000ng/ml down to 1ng/ml, helps to preserve the cytotoxicity of the samples to an allogeneic stimulus and maintains the susceptibility of the T cells to the retroviral transduction. Aiming to reduce the cost of the manipulation procedure, we also tried to reduce the amount of anti-CD28 MoAb during the activation (pre-infection) and expansion (post-infection) steps. To investigate this issue, different doses of anti-CD28i were combined either with 1,000 ng/ml or with 10 ng/ml of anti-CD3i. In contrast to the effects observed with anti-CD3i, lowering the dose of anti-CD28i, from 1,000 ng/ml to a range of 500 to 10 ng/ml significantly decreased the transduction efficacy, as well as the total number of transduced T cells, regardless of the concentration of anti-CD3i used in the experiments. With the purpose of minimizing potential effects mediated by retroviral supernatants on the viability and growth of the T cells, we investigated whether standard infections with supernatants could be replaced by alternative or complementary transduction procedures based on the pre-loading of the retroviral vectors in fibronectin-coated bags. In these experiments, fibronectin-coated cell culture bags were pre-loaded with retroviral vectors by means of a 3h-incubation with the infective supernatants. Thereafter, peripheral blood lymphocytes were added to the culture bags, incubated O/N and then subjected to further infection cycles, either with pre-loaded vectors or with infective supernatants. Performing only one cycle of infection with either method, rendered similar low yields of transduced cells compared to results obtained after 2 infection cycles. Under these conditions, we found no differences between both methods, neither with respect to the transduction efficacy nor with the total number of transduced cells. Conducting a third infection cycle, either using the pre-loading or the supernatant infection method, did not increase significantly the transduction efficacy of the samples. Also, to simplify and improve the safety of the manipulation procedure, we studied alternatives to the use of human allogeneic or autologous serum for the supplement of the cell culture medium (RPMI). In these experiments, RPMI supplemented with 10% autologous serum was replaced by the CellGro and X-Vivo 10 serum-free media. Similar transduction efficacies and similar number of transduced cells were generated as a result of the manipulation of the samples with either medium. We conclude that optimised conditions of T cell stimulation and gene expression are obtained with 1ng/ml anti-CD3i and 1,000 ng/ml anti CD28i, and that conventional supernatant infections conducted with serum-supplemented media can be partially or completely replaced by pre-loading infections in serum-free media. We propose these manipulations to simplify and to reduce risks and costs associated to the transduction of human T cells; something that is of particular interest for the development of clinical protocols that require the infusion of large numbers of transduced T lymphocytes.


2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A724-A724
Author(s):  
David Ciccone ◽  
Vad Lazari ◽  
Ian Linney ◽  
Michael Briggs ◽  
Samantha Carreiro ◽  
...  

BackgroundHPK1, a member of the MAP4K family of protein serine/threonine kinases, is involved in regulating signal transduction cascades in cells of hematopoietic origin. Recent data from HPK1 knockout animals and kinase-inactive knock-in animals underscores the role of HPK1 in negatively regulating immune cell activation. This negative-feedback role of HPK1 combined with its restricted expression in cells of hematopoietic origin, make it a compelling drug target for enhancing anti-tumor immunity.MethodsA structure-based drug design approach was used to identify potent and selective inhibitors of HPK1. Biochemical assays, as well as primary human and mouse immune cell-based activation assays, were utilized for multiple iterations of structure-activity relationship (SAR) studies. In vivo efficacy, target engagement and pharmacodynamic data were generated using murine syngeneic tumor models.ResultsA highly potent, HPK1 inhibitor was identified, that showed high selectivity against T cell-specific kinases and kinases in the MAP4K family. In vitro, HPK1 small molecule inhibition resulted in enhanced IL-2 production in primary mouse and human T cells, enhanced IL-6 and IgG production in primary human B cells, and enhanced mouse dendritic cell activation and antigen presentation capacity. Furthermore, HPK1 inhibition alleviated the immuno-suppressive effects of PGE2 on naïve human T cells and restored the proliferative capacity of exhausted human T cells. In vivo, HPK1 inhibitionHPK1 inhibition abrogated T cell receptor-stimulated phospho-SLP-76, enhanced cytokine production, and mediated robust tumor growth inhibition in a murine syngeneic tumor model.ConclusionsPharmacological blockade of HPK1 kinase activity represents a novel and potentially valuable immunomodulatory approach for anti-tumor immunity.


2019 ◽  
Author(s):  
Enas Abu-Shah ◽  
Philippos Demetriou ◽  
Stefan Balint ◽  
Viveka Mayya ◽  
Mikhail A. Kutuzov ◽  
...  

AbstractResearch in the field of human immunology is restricted by the lack of a system that reconstitutes the in-situ activation dynamics of quiescent human antigen-specific T-cells interacting with dendritic cells. Here we report a tissue-like system that recapitulates the dynamics of engineered primary human immune cell. Our approach facilitates real-time single cell manipulations, tracking of interactions and functional responses complemented by population-based measurements of cytokines, activation status and proliferation. As a proof of concept, we recapitulate immunological phenomenon such as CD4 help to CD8 T-cells through enhanced maturation of DCs and effect of PD-1 checkpoint blockades. In addition, we characterise unique dynamics of T-cell/DC interactions as a function of antigen affinity.


Sign in / Sign up

Export Citation Format

Share Document